### 1 **Genomic characterization of invasive typhoidal and non-typhoidal** *Salmonella* **in**

#### 2 **southwestern Nigeria**



- <sup>7</sup> Centre for Genomic Pathogen Surveillance, Big Data Institute, University of Oxford,
- 26 Oxford, United Kingdom.
- 27 <sup>8</sup> Nigeria Centre for Disease Control, Jabi, Abuja, Nigeria.

# 28 ABSTRACT

29 **Background:** Salmonellosis causes significant morbidity and mortality in Africa. Despite 30 being endemic in Nigeria, information on circulating lineages of invasive *Salmonella* is 31 sparse.

32 **Methods:** *Salmonella enterica* isolated from blood (n=60) and cerebrospinal fluid (CSF, 33 n=3) between 2016 and 2020 from five tertiary hospitals in southwest Nigeria were 34 antimicrobial susceptibility-tested and Illumina-sequenced. Genomes were analysed using 35 publicly-available bioinformatic tools.

36 **Results:** Isolates and sequence types (STs) from blood were *S*. Typhi [ST1, n =1 and ST2, n

37 =43] and invasive non-typhoidal *Salmonella* (iNTS) (*S*. *Enteritidis* [ST11, n=7], *S*. Durham 38 [ST10, n=2], *S*. Rissen [ST8756, n=2], *S*. Chester [ST2063, n=1], *S*. Dublin [ST10, n=1], *S*. 39 Infantis [ST603, n=1], *S*. Telelkebir [ST8757, n=1] and *S*. Typhimurium [ST313, n=1], *S*. 40 Typhi ST2 (n=2) and *S*. Adabraka ST8757 (n=1) were recovered from CSF. Most *S.* Typhi 41 belonged to genotype 3.1.1 (n=44), carried an IncY plasmid and had several antibiotic 42 resistance genes (ARGs) including *bla*TEM-1 (n=38), *aph(6)-Id* (n=32), *tet(A)* (n=33), *sul2* 43 (n=32), *dfrA14* (n=30) as well as quinolone resistance-conferring gyrA\_S83Y SNPs (n=37). 44 All *S*. Enteritidis harboured *aph(3'')-Ib*, *bla*TEM-1, *catA1*, *dfrA7*, *sul1*, *sul2*, *tet(B)* genes, and 45 a single ARG, *qnrB19,* was detected in *S*. Telelkebir.. Typhoidal toxins *cdtB*, *pltA* and *pltB*  46 were detected in *S*. Typhi, Rissen, Chester, and Telelkebir. 47 **Conclusion:** Most invasive salmonelloses in south west Nigeria are vaccine-preventable 48 infections due to multidrug-resistant, West African dominant Typhi lineage 3.1.1.. Invasive

49 NTS serovars, including some harbouring typhoidal toxin or resistance genes represented a

50 third of the isolates emphasizing the need for better diagnosis and surveillance.

51

53

# 54 **Author Summary**

- 55 Whole genome sequencing of 63 invasive *Salmonella* from 5 tertiary hospitals in Nigeria
- 56 revealed multiple serovars including a dominant antibiotic-resistance-gene harbouring *S*.
- 57 Typhi 3.1.1 genotype comprising a gyrA\_S83Y and IncY plasmid. We also report invasive
- 58 non-typhoidal *Salmonella* harbouring typhoidal toxins.
- 59

### 61 *INTRODUCTION*

62 *Salmonella* are a group of Gram negative, motile, facultative anaerobic rod-shaped bacteria 63 belonging to the *Enterobacteriaceae* family. This genus consists of two known species, 64 *Salmonella enterica* and *Salmonella bongori*. *S. enterica* are further distributed across six 65 subspecies, of which the *S. enterica* subsp. *enterica* are most reported in infections involving 66 homeotherm animals [1]. Furthermore, *S. enterica* subsp. *enterica* consists of over 1500 67 serovars with distinct antigenic specificity [2] . The human host-adapted *S. enterica* subsp. 68 *enterica* serovars are usually associated with three marked clinical syndromes: *Salmonella*  69 *enterica* subsp. *enterica* serovar Typhi cause typhoid fever, and the non-typhoidal *Salmonella* 70 (NTS) cause bacteraemia and gastroenteritis in immunocompromised (including persons with 71 advanced HIV disease, cases of severe malaria and malnutrition in children) and 72 immunocompetent persons, respectively [3,4]. *S*. Paratyphi A, B and C produce a syndrome 73 similar to typhoid fever.

74 The public health impact of typhoidal and invasive non-typhoidal *Salmonella* infections is 75 significant particularly in Africa and Asia where they have a great influence on morbidity and 76 mortality [5,6]. For instance, an estimated 17.8 million cases of typhoid fever occur each year 77 in low and middle-income countries (LMICs) [7]. An earlier estimate suggests that the 78 burden of typhoid fever is >100 per 100000 individuals per annum in sub-Saharan Africa 79 with an associated 1% mortality [8,9]. Furthermore, an estimated 26% (33,490 lives lost) of 80 the annual global typhoid-related mortality is reported to occur in Africa [9]. The disease 81 burden of typhoid in Nigeria is estimated at 364,791 typhoid cases resulting in 4,232 deaths 82 (affecting 68% of individuals under 15 years of age) as at 2016 [10], however population-83 based data are only just becoming available [11]. Globally, NTS is estimated to cause 84 approximately 94 million cases of gastroenteritis per annum worldwide with a resultant 85 mortality of 155,000 [12]. In immunocompromised cases of the disease (amongst HIV-

86 positive adults), NTS is reported to cause a 20% case fatality (212,000 deaths) in sub-Saharan 87 Africa (SSA) annually, while also being responsible for over 1 million cases of bloodstream 88 infections in children in SSA with a case fatality of 18.1% (197,000 child mortality) 89 [4,13,14].

90 Although available reports suggest infection with *Salmonella enterica* to be the most 91 common cause of bloodstream infections in Africa [15], the incidence and microbiology of 92 typhoidal and invasive non-typhoidal *Salmonella* (iNTS) is still poorly understood. Many 93 regions on the continent have garnered little or no attention in the literature [7]. Blood 94 culture-based surveillance represents the standard method for assessing the epidemiology and 95 aetiology of bacterial invasive infections [16]. Limited surveillance of invasive *Salmonella* on 96 the Africa continent is majorly due to financial, logistical, and infrastructural constraints for 97 the institution and maintenance of blood culture-based surveillance systems in the region 98 [7,8,16,17].

99 Such limitations not only obscure the true burden and prevalence of invasive *Salmonella* 100 infections in resource-limited settings but also limit opportunity for genomic surveillance of 101 this pathogen. For instance, despite the huge burden of typhoid infections in Nigeria, before 102 the current study, there were only 131 *Salmonella* genomes (all *S*. Typhi) from the country on 103 Pathogenwatch (https://pathogen.watch/, 15th November 2021) [18], a web-based platform 104 for surveillance of microbial genomes all of which were collected on or before 2013, and 105 most from only two centres [19]. Lack of genomic surveillance information of invasive 106 *Salmonella* in resource-limited countries, including Nigeria, may deter interventions 107 necessary to ameliorate this burden, such as the typhoid conjugate vaccines [8,17,19,20]. 108 Hence, this report provides genomic characterization of 2016-2020 invasive *Salmonella* 109 retrieved from tertiary hospitals enrolled into Nigeria's Antimicrobial Surveillance Network 110 coordinated by the Nigeria Centre for Disease Control (NCDC).

 $\sim$  6



112

#### 113 *MATERIALS AND METHODS*

#### 114 **Ethical considerations**

115 Isolates were obtained as part of the surveillance efforts in line with Nigeria's national action 116 plan. Ethical approval for using them in research was obtained from the University of 117 Ibadan/University College Hospital ethics committee (UI/EC/15/093). Patient consent was 118 not obtained and the data were analysed anonymously.

119

# 120 **Isolate collection, Identification and Antimicrobial Susceptibility Testing**

121 Tertiary hospitals located in southwest Nigeria and enrolled into the Nigeria Antimicrobial 122 Surveillance Network provided cryopreserved isolates from blood and cerebrospinal fluid to 123 the AMR National reference laboratory. The isolates were from retrospectively batched 124 periods of 2016-2018 (retrospective isolates), 2019 and 2020. The national reference lab in 125 partnership with the Global Health Research Unit for the Genomic Surveillance of 126 Antimicrobial Resistance (GHRU-GSAR) conducted the re-identification of the isolates 127 using the Gram-negative (GN) test kit on (Ref: 21341) on VITEK 2 systems (version 2.0, 128 Marcy-l'Etoile, France, Biomérieux). Briefly, the cryopreserved isolates (at -80 °C) are 129 resuscitated before use for reidentification by subculturing onto Salmonella-Shigella Agar 130 and incubated aerobically at 37°C. Isolated colonies from pure cultures are the streaked on 131 Nutrient Agar (NA), incubated aerobically at 37°C. Isolated colonies on NA is then used to 132 prepare inoculum for VITEK using GN cards. This test is based on forty-seven biochemical 133 tests and a negative control. The cards contain wells with substrates for the different tests in 134 dried form. The cards are inoculated with a saline suspension of the organisms before 135 incubation. Upon incubation, biochemical reactions are read by the machine and recorded as

136 positive or negative. A bionumber which is based upon the combination of different test 137 results is then generated. The bionumber is compared to VITEK 2 robust database to match 138 the organism and this is used to identify the organism. An added step for confirming identity 139 of VITEK-identified isolates utilized whole-genome sequencing of all isolates. Antimicrobial 140 susceptibility testing was done using VITEK AST N280 test kit (Ref: 413432). N280 Cards 141 are incubated within the VITEK 2 compact upon inoculation with appropriate saline 142 suspension of test organism. The minimum inhibitory concentration (MIC) is recorded as the 143 highest concentration of an antibiotic for which no bacterial growth is observed. The MICs 144 were interpreted as either resistant, intermediate or susceptible in accordance to CLSI 145 standards [21].

146

## 147 **DNA extraction and Library preparation**

148 The isolates were processed for the extraction of genomic DNA using Wizard DNA 149 extraction kit (Promega; Wisconsin, USA) following manufacturer's instructions. The 150 extracted DNA was quantified on a Qubit fluorometer (Invitrogen; California, USA) using 151 dsDNA Broad Range quantification assay. Double-stranded DNA libraries were prepared 152 using the Covaris LC220 for fragmentation, and NEBNext Ultra II FS DNA library kit for 153 Illumina with 384-unique indexes (New England Biolabs, Massachusetts, USA; Cat. No: 154 E6617L). Libraries were sequenced on an Illumina HiSeq X10 (Illumina, California, USA).

155

156

#### 157 **Genome Assembly**

158 Generated sequence reads from Illumina runs were *de novo* assembled following GHRU 159 protocols (https://gitlab.com/cgps/ghru/pipelines/dsl2/pipelines/assembly) using a Nextflow 160 workflow which inclusively comprises of adapter trimming (trimmomatic v0.38),

161 contamination detection (ConFindr v0.7.2), assembly (SPAdes v3.12.0), Quality Control

162 (multiqc v1.7, qualifyr v1.4.4) and Bactinspector (v 0.1.3).

163

## 164 **Sequence typing of** *Salmonella* **genomes**

165 Sequence reads were deposited in the *Salmonella* database on EnteroBase [22]. Multi-locus 166 sequence types (MLST) for the isolates were determined and core-genome MLST calculated. 167 Evolutionary relationship based on cgMLST of all *S*. Typhi of human origin from Africa 168 deposited in Enterobase were determined [22]. The *Salmonella* genome assemblies were 169 analysed using the *Salmonella* In-Silico Typing Resource (SISTR) for the prediction of 170 serovars and serogroups (https://github.com/phac-nml/sistr\_cmd). Genomes belonging to *S.* 171 Typhi were loaded unto Pathogenwatch for the prediction of their genotypes [18].

172

#### 173 **Identification of AMR, Plasmids, Virulence genes and** *Salmonella* **Pathogenicity islands**

174 Determinants of AMR, virulence and plasmid replicons were identified following GHRU 175 protocols (https://gitlab.com/cgps/ghru/pipelines). Prediction of *Salmonella* pathogenicity 176 islands (SPIs) in the genomes was done by mapping raw reads to SPIs database

177 (https://bitbucket.org/genomicepidemiology/spifinder\_db)

178

## 179 **Single Nucleotide Polymorphism (SNP) calling and phylogeny**

180 The sequence reads of the *S.* Typhi and *S.* Enteritidis genomes from our study were mapped 181 to NCBI reference sequence, *Salmonella* enterica subsp. enterica serovar Typhi strain 182 H12ESR00755-001A (assembly accession: GCF\_001362195.2) and *Salmonella* enterica 183 subsp. enterica serovar Enteritidis strain 18569 (assembly accession: GCF\_000335875.2), 184 respectively, to determine evolutionary relationship amongst the strains following GHRU 185 nextflow SNP phylogeny protocols (https://gitlab.com/cgps/ghru/pipelines/snp\_phylogeny).

186 Briefly, reads were trimmed (trimmomatic v0.38) and mapped to the reference genomes 187 described above using bwa mem (v0.7.17) and variants were called and filtered using 188 bcftools (v1.9). A pseudoalignment with the reference was used to generate a maximum 189 likelihood tree using iqtree (v1.6.8) [23]. SNP distances between the genome pairs were 190 calculated using snp-dists v.0.8.2 (https://github.com/tseemann/snp-dists) on the pseudo-191 genome alignment.

192

# 193 **Availability of sequence data**

194 Raw sequence data generated from this study are deposited in the European Nucleotide 195 Archive under Bioproject PRJEB29739. Accession numbers for each genome is available in 196 Supplementary Table 1.

197

198 *RESULTS* 

### 199 **Invasive** *Salmonella* **from sentinel hospitals from Nigeria's AMR Surveillance Network**

200 Using the VITEK system for bacterial identification described above, a total of 69 isolates 201 retrieved from patients from five (n=5) sentinel hospitals were identified as *Salmonella* spp., 202 at the reference laboratory. However, results from whole-genome sequencing confirmed n=61 203 of these to be *Salmonella enterica*. In addition, two other isolates from our surveillance 204 collection initially identified as *Escherichia coli* and *Acinetobacter baumanii* using VITEK 205 were subsequently identified as *Salmonella enterica* using WGS.

206 The sixty-three (63) WGS-confirmed invasive *Salmonella* isolates have average number of

207 contigs was 58 and N50 values ranged from 172132bp to 731013bp (average 246872 bp).

208 The G+C (%) content of the genomes ranged from 51.86% - 52.37% (average 52.10%)

209 (Supplementary Table 1). The isolates were retrieved from blood  $(n=60)$  and cerebrospinal

210 fluid (n=3). The sending sentinel hospitals include: University of Ilorin Teaching Hospital

211 (ILO, Ilorin, Kwara State, n=25), University College Hospital, Ibadan (UCH, Ibadan, Oyo 212 State, n=23), Obafemi Awolowo University Teaching Hospital, Ile-Ife (OAU, Ile-Ife, Osun 213 State, n=8), Lagos University Teaching Hospital (LUT, Idi-Araba, Lagos State, n=4) and 214 Babcock University Teaching Hospital (BUT, Ilishan-Remo, Ogun State, n=3) (Fig. 1A). 215 Majority of the isolates were retrieved in 2019 from ILO (n=22). Thirteen isolates had no 216 year specified metadata but were retrospective isolates retrieved between 2016 and 2018 (Fig 217 1A). The hospitals are all in the southwestern part of Nigeria with ILO just north of the 218 South-West geopolitical zone and all the rest within it. All the *Salmonella* isolates from 219 cerebrospinal fluid were obtained from LUT.

220

#### 221 **Distribution of** *Salmonella enterica* **subsp.** *enterica serovars* **across sentinel hospitals**

222 All the *Salmonella enterica* isolates belonged to the subspecies *enterica* but differed by

223 serotype with a total of 10 serovars detected. They include Typhi  $(n=46)$ , Enteritidis  $(n=7)$ ,

224 Durham (n=2), Rissen (n=2), Adabraka (n=1), Chester (n=1), Dublin (n=1), Infantis (n=1),

225 Telelkebir (n=1), Typhimurium (n=1). Three *Salmonella enterica* isolates belonging to

226 serovars Adabraka (n=1) and Typhi (n=2) were retrieved from cerebrospinal fluid from LUT.

227 All other *Salmonella* serovars were retrieved by blood culture at the respective sentinel sites

228 (Supplementary Table 1). *Salmonella* Typhi and iNTS were recovered from all sentinel sites,

229 with iNTS being much less frequently recovered (Fig. 1B).

# 230 **Sequence types, genotypes, and nucleotide polymorphisms.**

231 *Salmonella* sequence-typing based on Achtman's MLST scheme [24] identified two *S*. Typhi

232 Sequence Types (STs) (ST1 =1 and ST2 = 45). There were nine different iNTS STs. These

- 233 included previously reported invasive STs: *S* Enteritidis ST11 (n=7) and *S* Typhimurium
- 234 ST313 (n=1), which are repeatedly reported from Africa. Other iNTS were *S*. Dublin (ST10),
- 235 *S*. Infantis (ST603), *S*. Durham (ST2010), *S*. Chester (ST2063), *S*. Telelkebir (ST2222). Two

236 novel STs belonging to *S*. Rissen and *S*. Adabraka were curated and designated STs 8756 and 237 8757 respectively by EnteroBase.

238 To further place our *S.* Typhi genomes in a wider context, we performed cgMLST analysis 239 based on differences in core genomes of our strains and all *S*. Typhi from human sources in 240 Africa deposited in EnteroBase (n=980) (Fig 2). All genomes included in this study had 241 similar core genome allelic differences at HC400, whereas at HC200 genomes from this 242 study had similar allelic profile with 98.06% (n=961) of the genomes in the population. 243 Genomes accounting for the difference in cluster numbers in the population at HC400 were 244 from Nigeria (n=9, ~0.92%), Cameroon (n=4, ~0.41%) Algeria (n=3, ~0.3%) Morocco (n=2, 245 0.2%) and Senegal (n=1, 0.1%). Generally, *S*. Typhi genomes from this study clustered with 246 others from West Africa, including Nigeria, Cameroon, Togo, Mauritania, Mali, Burkina 247 Faso, Guinea, Benin, and Ivory Coast, emphasizing further on their endemicity in the West 248 Africa region (Fig 2).

249 Further, based on *S*. Typhi genotyping scheme, we observed that the isolate of *S*. Typhi ST1 250 belonged to genotype 4.1 (UCH), whereas genotypes 2.3.1 (n=1, UCH) and 3.1.1 (n= 44) 251 were *S*. Typhi ST2 isolates. In addition, *S*. Typhi genomes from CSF (n=2) belonged to the 252 3.1.1 genotype. To further investigate the genetic relatedness of the genomes in this study, we 253 report outcome of pairwise SNP differences among the genomes. Pairwise SNP difference 254 ranged from 401 to 431 between *S*. Typhi 4.1 and other *S*. Typhi genotypes in this study, 255 whereas it was 401 to 521 between *S.* Typhi 2.3.1 and other *S.* Typhi genotypes. The 256 dominant Typhi genotype, *S.* Typhi 3.1.1 were 0 to 47 SNPs apart (Supplementary Table 3). . 257 Among *S*. Enteritidis, pairwise SNP difference ranged from 0 to 44 in the three sentinel labs 258 (UCH, OAU, ILO) where they were isolated. One pair of *S*. Enteritidis isolates from UCH 259 were identical and the third isolate was 33 SNPs apart from them. The three *S*. Enteritidis

260 isolates from ILO (n=3) were near identical having pairwise SNP range from 0 to 1 261 (Supplementary Table 4).

262

## 263 **Antimicrobial susceptibility profiles, antimicrobial resistance determinants and**

# 264 **plasmids replicons in TS and NTS**

265 Antimicrobial susceptibility testing revealed majority of the *S.* Typhi to be resistant to 266 sulphamethoxazole/trimethoprim (SXT) and ampicillin (n=41 each) and nalidixic acid 267 (n=36), of which three were ciprofloxacin non-susceptible, according to CLSI (2021) criteria. 268 (Supplementary Table 2). While not relevant to the antimicrobial chemotherapy of invasive 269 infections, resistance to nitrofurantoin was identified in the n=2 *S*. Typhi isolated from CSF 270 and in n=9 isolates from blood with the highest MICs ( $128 \mu g/mL$ ) seen in the CSF isolates 271 only. Resistance to cephalosporins, cefuroxime and cefuroxime axetil was observed in *S*. 272 Typhi 3.1.1 from UCH.

273 The single *S.* Typhi 2.3.1 isolate was resistant to ampicillin and SXT whereas no phenotypic 274 resistance was observed with *S.* Typhi 4.1. All *S.* Enteritidis and *S.* Typhimurium were 275 resistant to ampicillin and sulphamethoxazole/trimethoprim. Asides Telelkebir harbouring 276 resistance to nalidixic acid and ciprofloxacin, other NTS were either susceptible or 277 intermediately resistant to other antimicrobials (Supplementary Table 2). For example, *S.* 278 Adabraka, Dublin and Telelkebir were intermediately resistant to cefuroxime axetil. 279 (Supplemental Table 2 and microreact link for antimicrobial susceptibility testing:

280 https://microreact.org/project/ahQ3Yb64nsbnhHMzz3WQn9-genomic-epidemiology-of-

281 invasive-salmonella-in-southwestern-nigeria-ast-data)

282

283 A combined total of 14 acquired antimicrobial resistance genes (ARGs) conferring resistance

284 to drugs within seven antibiotic classes were detected amongst the genomes. Amongst the *S*.

285 Typhi genomes, n=36/46 harboured at least one ARG conferring reduced susceptibility to 5 286 antibiotic classes, with n=41 harbouring a sulphonamide resistance gene [*sul1* =9/46, *sul2* = 287 33/46)] and n=39 each harbouring a beta-lactam (*bla*<sub>TEM-1</sub>), tetracyclines (*tetA*, n=33 and *tetB*, 288 n=6), and trimethoprim resistance determinant (*dfrA1*, [n=1], *dfrA15* [n=8] and *dfrA14* 289 [n=30]). In addition, chloramphenicol resistance genes, *catA1*, were also detected in the 290 genomes (n=8). Point mutations identified among the sequenced *S*. Typhi isolates were those 291 associated with the quinolone resistance determining region (QRDR), gyrA\_S83Y SNPs 292 (n=37), which mediate resistance to fluoroquinolones (Fig 3). Furthermore, n=45 of the *S*. 293 Typhi genomes had at least one plasmid predicted to occur in each genome. Majority  $(n=33)$ 294 possessed an IncY plasmid replicon, plasmid replicons IncFIA\_HI1, IncHIA and IncHIB 295 were respectively detected in n=9 of *S*. Typhi genomes whereas one isolate harboured an 296 IncQ plasmid replicon (Fig 3).

297

298 For the iNTS, *S*. Enteritidis genomes possessed at least one ARG to six antibiotic classes. All 299 Isolates of this serotype harboured *aph(3")-Ib*, *bla*TEM-1, *catA1*, *dfrA7*, *sul1*, *sul2*, *tet(B)* 300 genes, and only differed in the absence/presence of *aph(6)-Id* (n=4) (Fig 4). In tandem, *S*. 301 Typhimurium harbour ARGs [*aadA1*, *aph(3'')-Ib*, *aph(6)-Id*, *bla*TEM-1, *catA1*, *dfrA1*, *sul1*, 302 *sul2*] encoding resistance to 5 antibiotic classes (Fig 5). The only occurring quinolone 303 resistance gene among isolates in this study, *qnrB19*, was detected in *S*. Telelkebir. No ARGs 304 were detected in *Salmonella* serovars Chester, Rissen, Durham, Infantis, Adabraka and 305 Dublin. Antimicrobial point mutations identified among iNTS were associated with *gyrA* and 306 *parC* gene regions (Fig 5). The quinolone resistance conferring gyrA\_D87Y SNPs were 307 identified only amongst *S*. Enteritidis (ILO,  $n = 3$  and UCH,  $n = 1$ ), whereas the parC\_T57S 308 mutations were detected in all iNTS except *S*. Enteritidis and *S*. Typhimurium. Plasmids



313 We observe that all *S*. Typhi of the 3.1.1 lineage harbouring an IncY plasmid replicon 314 (n=33/46) similarly possessed the gyrA\_S83Y chromosomal gene mutation and harboured a 315 *tetA* gene. Although other antimicrobial resistance genes were seen at slightly lower numbers 316 (n=  $32/33$  for *sul2* and *aph(6)-Id* and n=30/33 for  $bla_{\text{TEM-1}}$  and  $dfrA14$ ), the 317 IncY+gyrA\_S83Y+*tetA* in *S.* Typhi 3.1.1 phenomenon was observed to occur in all the 318 sentinel hospitals in this study. Additionally, maximum pairwise SNP distance between the 319 variants in this cluster was 23. This is approximately twice as less of what was determined in 320 *S*. Typhi 3.1.1 outside this cluster (n=47), thereby, emphasizing clonality within this cluster.

321

#### 322 *Salmonella* **virulence determinants and predicted pathogenicity islands**

323 The isolates possessed a plethora of virulence determinants (Supplementary Table 2). Among 324 the *S*. Typhi genomes, a total of 98 virulence determinants were detected, and 97 of these 325 were conserved within members of this serovar (with the exception of *pipB2* gene in an *S*. 326 Typhi 3.1.1 from UCH).

327 A total of 106 virulence genes were detected among the *S*. Enteritidis genomes, 104 of these 328 were conserved within these genomes, with 2 strains from UCH lacking either a *Salmonella*  329 secreted protein H (*sspH*) or secretion system effector I (*sseI*). A total of 122 virulence genes 330 were detected in the iNTS genomes, and n=86 of these were conserved in all iNTS genomes. 331 For instance, the iNTS possessed genes encoding (i) Adherence; such as *agf* – thin 332 aggregative fimbrae or curli (*csgABCDEGF*), *misl* – an autotransporter protein, *pef* - plasmid-333 encoded fimbrae (present only in *S*. Typhimurium) *ratB* (carried by iNTS strains harbouring

334 CS54 islands), *shdA* (only found in *S*. Infantis), *sinH* (detected in all NTS except *S*. 335 Enteritidis) and Type 1 fimbrae (*fimCDFHI*) (ii) Stress adaptation; *sodCI* – superoxide 336 dismutase (detected in iNTS serovars except Durham, Chester and Rissen and Infantis and 337 Telelkebir), *sopA* (not detected in *S*. Infantis) (iii) Nutritional/metabolic factor (*mgtBC*, 338 present in all strains) (iii) Antimicrobial activity/competitive advantage; such as macrophage 339 inducible genes (*mig-14*, present in all strains) and (iv) Enterotoxin; T3SS effectors – *spvBC* 340 (in *S*. Typhimurium, Enteritidis and Dublin), *avrA* (in all iNTS except *S*. Dublin) and 341 Typhoidal toxin - *cdtB* (present in *S*. Durham, *S*. Telelkebir and *S*. Chester).

342 Since the *cdtB* are reported to be co-located with other cytolethal distending toxins (*cdt*), 343 pertussis-like toxins A (*pltA*) and B (*pltB*), on same pathogenicity islet [25], we ran a blast 344 search of our strains for the presence of *pltA* and *pltB*. The nucleotide sequences were 345 extracted from the virulence factor database (VFDB) and used as a local database for a blast 346 search against our iNTS genomes. Our results reveal high similarity (100% coverage and  $\geq$ 347 96.62% identity) with *cdtB*, *pltA* and *pltB* genes in the iNTS genomes (*S*. Chester, *S*. Durham 348 and *S*. Telelkebir).

349

350 Eleven and twelve *Salmonella* pathogenicity islands (SPIs) were predicted in *S*. Typhi and 351 iNTS genomes, respectively (Fig 6). All *S*. Typhi were predicted to have 10 SPIs, i.e., SPI-1, 352 SPI-2, SPI-3, SPI-4, SPI-5, SPI-6, SPI-7, SPI-8, SPI-9, SPI-10 and SPI-12. However, SPI-4 353 was predicted to occur only in *S*. Typhi lineages 2.3.1 and 4.1. In contrast to *S*. Typhi, only 354 SPI-3 was predicted to occur in all the iNTS genomes. Certain SPIs were shown to be 355 associated with members of certain serovars. For instance, SPI-2 and SPI-8 were detected 356 only in *S*. Typhimurium and *S*. Rissen, respectively. Other pathogenicity islands were 357 detected in this study (Fig 3), such as SPI-4 (*S*. Adabraka, Chester, Typhimurium), SPI-6 (all 358 NTS except *S*. Durham, Rissen and Telelkebir), SPI-12 (all NTS except S. Chester, Durham,

359 Rissen and Telelkebir) and CS54\_island was detected in *S*. Dublin, *S*. Typhimurium, *S*. 360 Infantis and *S*. Enteritidis (n=6).

361

362 *DISCUSSION* 

363 In this report we present the outcome of genomic characterization of invasive *Salmonella* 364 infections from AMR surveillance in sentinel hospitals in Nigeria. The genomic 365 characterization of invasive *Salmonella* isolates in this study was possible because these 366 hospitals perform blood culture and are enrolled in Nigeria's new antimicrobial resistance 367 surveillance system, which offers genomic services at the National Reference Laboratory 368 level [26]. Nonetheless, blood culture is available at very few institutions in Nigeria, a 369 limitation still prevalent in many African settings that impacts the genomic surveillance of 370 invasive *Salmonella*. [8,16,27]. Moreover, these sentinels perform very few blood cultures so 371 that the isolates studied here represent a very small proportion of circulating strains.

372

373 Using high-throughput WGS and bioinformatic analytics, we were able to determine 374 prevalent serotypes and dominant genotypes of invasive *Salmonella* infections. Most of the 375 *Salmonella* isolates cultured from blood were *S.* Typhi, as has been previously reported from 376 different parts of Nigeria, including Ibadan [28–30], even though iNTS may predominate in 377 some other African settings [3,31]. While our data are few, the predominance of Typhi at all 378 sites points to a significant burden of severe disease that could be averted if Typhoid 379 Conjugate Vaccines were deployed in Nigeria. Out of a total of 10 *S*. Typhi genotypes 380 recorded from Nigeria in Pathogenwatch, three were identified in this study. The *S*. Typhi 381 genotype 3.1.1 we report was similarly common in the Nigeria cluster on Pathogenwatch 382 (n=87/131). As in our study, this cluster possessed similar prevalence of genetic determinants 383 of beta-lactam (*bla*TEM-1 – 83.90%) resistance, indicating that these determinants are well-

384 conserved in the genotype. However, prevalence of other AMR genetic determinants from 385 this lineage such as *catA1*, *sul1*, *sul2*, *dfrA14*, *dfrA15*, *tetA*, *tetB* were similar with what is 386 reported from this study, but at different rates.

387 This multidrug-resistance gene-encoding *S*. Typhi 3.1.1 is shown to be one of the broadest 388 lineages in sub-Saharan Africa and endemic in the West Africa region [19,32,33]. This *S.* 389 Typhi genotype is frequently reported to multidrug and ciprofloxacin resistant [29,31]. All S. 390 Typhi 3.1.1 (except one from OAU) harbouring quinolone-conferring SNPs in *gyrA* showed 391 phenotypic resistance to nalidixic acid. Additionally, we observed that the *S*. Typhi genotype 392 3.1.1 clone variants harboured an IncY + gyrA\_S83Y + *tetA* genes. The Pathogenwatch 393 database includes three *S*. Typhi 3.1.1 strains isolated from blood samples in 2013, in Abuja, 394 north-central capital of Nigeria with similar clonal characteristics (having same genotype, 395 plasmid replicon, chromosomal QRDR and antimicrobial resistance gene, *tetA*) [19]. Outside 396 Nigeria, this lineage has also been identified in the United Kingdom (accession: 397 SRR7165434, SRR5585020) [32]. Our data suggest that this resistant sub-lineage is 398 predominant in our setting and should be sought elsewhere in Nigeria and the region. In 399 addition, long read sequencing to unveil the carriage of the IncY plasmids would be 400 potentially vital to understanding the success of this lineage in Nigeria.

401

402 *S*. Enteritidis were the most frequently recovered iNTS in our study and sent from three 403 sentinel hospitals. This outcome contrasts with earlier reports of *S*. Typhimurium ST313 as a 404 predominant serotype in eastern and southern Africa, but also present across the continent, 405 including Nigeria [15,34,35], but it is concordant with more recent reports describing *S*. 406 Enteritidis in higher proportions in invasive infections in The Gambia [36]. Several of the *S.* 407 Enteritidis in our study were multidrug resistant (resistant to ampicillin, SXT, nalidixic acid). 408 This multidrug resistant clone has also been reported in bacteraemia in other parts of Africa

409 [37,38]. We observed that *S*. Enteritidis retrieved from different patients in ILO (in 2019) had 410 highly similar genetic features (antimicrobial resistance determinants, virulence, plasmids 411 replicons) and clustered together at 0-1 SNP distances between them. The isolates were 412 recovered on the  $27<sup>th</sup>$  of June,  $26<sup>th</sup>$  of August and  $28<sup>th</sup>$  of August 2019 and their genetic, 413 geographic and temporal connectedness may be indicative of a previously unrecognized 414 outbreak. Both *S*. Typhimurium ST313 and *S*. Enteritidis ST11 are dominant, human-adapted 415 clones in sub-Saharan Africa [38] and are a major cause of invasive disease, with a 416 corresponding high case-fatality rate [14]. These serovars are justifiably vaccine development 417 priorities. Non typhoidal *Salmonella* serovars, such as Dublin, Infantis, Chester, Rissen have 418 been reported severally from food animals [39–43], their presence in human invasive human 419 infection may attest to concerns with water and food safety, including animal contact [44– 420 46]. Although no ARGs were detected in this genome of these serovars, they remain a public 421 health concern [46,47]. The single occurrence of an acquired quinolone resistance gene, 422 *qnrB19* in this study was detected in *S*. Telelkebir. The strain also harboured phenotypic 423 resistance to the quinolone, nalidixic acid and ciprofloxacin. *S.* Telelkebir has been reported a 424 few times in Africa (as seen in Enterobase, [48]), and are more commonly reported in parts of 425 Europe, China and USA [49]. The expansion of atypical *Salmonella* serovars in invasive 426 infections is associated with a high health burden [17,36]. Invasive NTS vaccines in the 427 pipeline may not cover all NTS serovars [50], and we identified several in this study, 428 harbouring an assortment of virulence and antimicrobial resistance determinants. This points 429 to the need for widespread and robust access to invasive *Salmonella* diagnostics in Nigeria to 430 elucidate on the burden and make a case for serovar vaccine priorities [17,36,49].[49][17,36] 431

432 Amongst a plethora of virulence determinants present on both *S.* Typhi and iNTS, we 433 observed that *S*. Telelkebir, *S*. Durham and *S*. Chester isolates harboured the cytolethal

434 distending toxin islet genes (*cdtB*, *pltA*, *pltB*) also known as typhoid toxin. These toxins were 435 originally thought to be restricted to serovars Typhi and Paratyphi A [51]. However, these 436 have now been reported in other NTS serovars including Bredeney, Javiana, Montevideo, 437 Schwarzengrund, and more recently in Telelkebir [52–54]. A literature search on PubMed 438 and Google Scholar revealed little information on these toxins being reported in *S.* Durham 439 and *S.* Chester. The cytolethal distending toxin islet cause DNA damage and cell cycle arrest 440 in impaired cells [55]. More implicatively, these genes encoded by NTS serovars have been 441 reported to play vital roles in disease pathogenesis [53,54]. Many of *Salmonella* virulence 442 determinants are clustered in pathogenicity island on the bacterial chromosome, playing key 443 roles in disease pathogenesis [56,57]. A variety of SPIs were identified in this study. The SPI-444 7 which were exclusively detected in *S*. Typhi in this study are known to be large and major 445 backbone constituent of *S.* Typhi, harbouring several virulence determinants including the Vi 446 antigen [58]. Like in this study, the CS54 island and SPI-14 island are more commonly 447 detected NTS [59–62], with scarce reports in *S.* Typhi, and the CS54 island are suggested to 448 have evolved over multiple horizontal transfers [63]. Thus, this study emphasizes on an 449 expanding number of serovars causing invasive infections in the country, and the public 450 health implications therein. Further studies focussed on molecular analysis of gene content of 451 SPIs in invasive *Salmonella* infections could be pertinent in understanding pathogenesis and 452 aid in the advancement of treatment options [64].

453

## 454 *CONCLUSION*

455 The outcome of our study emphasizes the need for expanded genomic surveillance of 456 invasive *Salmonella* infections in Nigeria as a valuable tool to monitor antibiotic resistance 457 spread and genetic characterization of circulating lineages in Nigeria. Close monitoring of the 458 dominant *S.* Typhi 3.1.1 clone harbouring the IncY plasmid replicon and gyrA\_S83Y

459 chromosomal mutation, identified in all the tertiary hospitals in this study, including other 460 serovars is vital, and this may help to establish strategies for empirical treatment and control 461 of spread of antibiotic resistant lineages. Furthermore, our data suggests that introducing 462 typhoid conjugate vaccines, recommended by the World Health Organization for countries 463 like Nigeria that have a high typhoid disease burden, will have a significant impact on health 464 [65]. Development of vaccines which target NTS would be useful in reducing the overall 465 burden of NTS on the continent. Rigorous surveillance plays an essential part in determining 466 which serovars most require coverage, as we observe *S.* Enteritidis to be most prevalent NTS 467 in invasive infections in southwest Nigeria, and hence recommended as vaccine priorities. 468 Importantly, broader protective effects may be achieved by improvements in water, sanitation 469 and hygiene that could interrupt transmission of the causes of typhoid and other invasive 470 salmonellosis.

471

472 *FUNDING* 

473 This work was supported by Official Development Assistance (ODA) funding from the

474 National Institute of Health Research https://www.nihr.ac.uk/ (grant number 16\_136\_111) to

475 DMA and INO and the Wellcome Trust https://wellcome.org/ grant number 206194 to DMA.

476 INO was an African Research Leader supported by the UK Medical Research Council

477 (MRC) https://mrc.ukri.org/ and the UK Department for International Development (DFID)

478 under the MRC/DFID Concordat agreement that is also part of the EDCTP2 program

479 supported by the European Union (Award # MR/L00464X/1) and is presently a Calestous

480 Juma Science Leadership Fellow supported by the Bill and Melinda Gates Foundation

481 https://www.gatesfoundation.org/ (Award # INV-036234). The funders had no role in study

482 design, data collection and analysis, decision to publish, or preparation of the manuscript.

483

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.01.28.22270011;](https://doi.org/10.1101/2022.01.28.22270011) this version posted May 23, 2022. The copyright holder for this preprint

## 484 *ACKNOWLEDGEMENT*

- 485 We thank Chinenye Ekemezie, Ifeoluwa J. Akintayo, Dorothy U Cyril-Okoh, Abeeb A.
- 486 Adeniyi and Ifeanyi E. Mba for excellent technical contributions and Jola-Ade J. Ajiboye for
- 487 logistic assistance. We are grateful to the administration and staff of the five sentinels for
- 488 supporting them in surveillance.
- 489
- 490
- 491
- 492
- 493
- 494

# 495 REFERENCES

496 1. Giner-Lamia J, Vinuesa P, Betancor L, Silva C, Bisio J, Soleto L, Chabalgoity JA, 497 Puente JL, Soncini FC, García-Vescovi E, Flores G, Pedraza J, Yim L, García C, 498 Astocondor L, Ochoa T, Hinostroza N, Graciela Pucciarelli M, Hernández-Alvarez A, 499 Del Moral V, García-Del Portillo F. Genome analysis of Salmonella enterica subsp. 500 diarizonae isolates from invasive human infections reveals enrichment of virulence-501 related functions in lineage ST1256. BMC Genomics. 2019 Jan 31;20(1):1–14. 502 2. Issenhuth-Jeanjean S, Roggentin P, Mikoleit M, Guibourdenche M, De Pinna E, Nair 503 S, Fields PI, Weill FX. Supplement 2008–2010 (no. 48) to the White–Kauffmann–Le 504 Minor scheme. Research in Microbiology. 2014 Sep 1;165(7):526–30. 505 3. Feasey NA, Dougan G, Kingsley RA, Heyderman RS, Gordon MA. Invasive non-506 typhoidal salmonella disease: an emerging and neglected tropical disease in Africa. 507 The Lancet. 2012 Jun 30;379(9835):2489–99. 508 4. Keestra-Gounder AM, Tsolis RM, Bäumler AJ. Now you see me, now you don't: the 509 interaction of Salmonella with innate immune receptors. Nature Reviews Microbiology 510 2015 13:4. 2015 Mar 9;13(4):206–16. 511 5. Smith SI, Seriki A, Ajayi A. Typhoidal and non-typhoidal Salmonella infections in 512 Africa. Vol. 35, European Journal of Clinical Microbiology and Infectious Diseases. 513 2016. p. 1913–22. 514 6. Phu Huong Lan N, Le Thi Phuong T, Nguyen Huu H, Thuy L, Mather AE, Park SE, 515 Marks F, Thwaites GE, Van Vinh Chau N, Thompson CN, Baker S. Invasive Non-516 typhoidal Salmonella Infections in Asia: Clinical Observations, Disease Outcome and 517 Dominant Serovars from an Infectious Disease Hospital in Vietnam. PLoS Neglected 518 Tropical Diseases. 2016 Aug 11;10(8):e0004857. 519 7. Antillón M, Warren JL, Crawford FW, Weinberger DM, Kürüm E, Pak GD, Marks F, 520 Pitzer VE. The burden of typhoid fever in low- and middle-income countries: A meta-











It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.01.28.22270011;](https://doi.org/10.1101/2022.01.28.22270011) this version posted May 23, 2022. The copyright holder for this preprint

- 770 61. Panzenhagen PHN, Cabral CC, Suffys PN, Franco RM, Rodrigues DP, Conte-Junior 771 CA. Comparative genome analysis and characterization of the Salmonella 772 Typhimurium strain CCRJ\_26 isolated from swine carcasses using whole-genome 773 sequencing approach. Letters in Applied Microbiology [Internet]. 2018 Apr 1 [cited 2022 May 4];66(4):352–9. Available from: 775 https://onlinelibrary.wiley.com/doi/full/10.1111/lam.12859 776 62. Cherchame E, Guillier L, Lailler R, Vignaud ML, Jourdan-Da Silva N, le Hello S, 777 Weill FX, Cadel-Six S. Salmonella enterica subsp. enterica Welikade: guideline for 778 phylogenetic analysis of serovars rarely involved in foodborne outbreaks. BMC 779 Genomics [Internet]. 2022 Dec 1 [cited 2022 May 4];23(1):1–13. Available from: 780 https://link.springer.com/articles/10.1186/s12864-022-08439-2 781 63. Kingsley RA, Humphries AD, Weening EH, de Zoete MR, Winter S, 782 Papaconstantinopoulou A, Dougan G, Bäumler AJ. Molecular and phenotypic analysis 783 of the CS54 island of Salmonella enterica serotype Typhimurium: Identification of 784 intestinal colonization and persistence determinants. Infection and Immunity [Internet]. 785 2003 Feb 1 [cited 2022 May 4];71(2):629–40. Available from: 786 https://journals.asm.org/doi/full/10.1128/IAI.71.2.629-640.2003 787 64. Kombade S, Kaur N. Pathogenicity Island in <em>Salmonella</em>. Salmonella spp - 788 A Global Challenge [Internet]. 2021 Mar 11 [cited 2022 May 4]; Available from: 789 https://www.intechopen.com/chapters/75674 790 65. WHO. WHO recommends use of first typhoid conjugate vaccine [Internet]. 2018 791 [cited 2021 Nov 26]. Available from: https://www.who.int/news/item/03-04-2018- 792 who-recommends-use-of-first-typhoid-conjugate-vaccine 793 794
- 795

## 797 **Figure Legends**

798 Fig 1: Epidemiological information showing: (A) number of Salmonella isolated received 799 from the different sentinel hospitals at different years, and (B) Number of different 800 *Salmonella* serotypes received from the different sentinel hospitals.

801

- 802 Fig 2: Grape tree showing core genome MLST of *S*. Typhi from human sources in Africa,
- 803 deposited in the EnteroBase database. Red leaf labels are genomes from this study

804

- 805 Fig 3: SNP-phylogeny based tree and gene presence/absence showing the genomic profile of
- 806 *Salmonella* Typhi genomes retrieved from 5 sentinel laboratories in Nigeria. ARGs: antibiotic
- 807 resistance genes, STs: Sequence types

808

- 809 Fig 4: SNP-phylogeny based tree and gene presence/absence map showing the genomic
- 810 profile of *Salmonella* Enteritidis retrieved from 3 sentinel laboratories in Nigeria. ARGs:
- 811 antibiotic resistance genes, STs: Sequence types.

812

813 Fig 5. Gene presence/absence map showing the genomic profile of non-typhoidal *Salmonella*

814 retrieved from 5 sentinel laboratories in Nigeria. ARGs: antibiotic resistance genes, STs:

- 815 Sequence types
- 816
- 817 Fig 6: Frequency of occurrence of *Salmonella* pathogenicity island in TS (Typhoidal 818 Salmonella) and NTS (Non-typhoidal Salmonella) in this study.















